Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 174

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 174
---
   |            — |   |
| Common stock ($0,0001 par value, 740,000,000 shares authorized; 6,951,622 shares                                                                                    
 issued and 5,493,356 shares outstanding as of December 31, 2024; 4,573,693 shares issued and 2,857,448 shares outstanding as of December 31, 2023, respectively(1)) |                                                               |   |            1 |   |     |   |            1 |   |
| Additional paid-in capital(1)                                                                                                                                       |                                                               |   |      454,614 |   |     |   |      407,828 |   |
| Accumulated other comprehensive income                                                                                                                              |                                                               |   |        6,317 |   |     |   |            — |   |
| Accumulated deficit                                                                                                                                                 |                                                               |   |     (563,052 | ) |     |   |     (490,245 | ) |
| Treasury stock, at cost; 1,716,245 shares as of each of December 31, 2024 and                                                                                       
 December 31, 2023                                                                                                                                                   |                                                               |   |      (90,522 | ) |     |   |      (90,522 | ) |
| Total stockholders’ deficit                                                                                                                                         |                                                               | $ |     (192,641 | ) |     | $ |     (172,938 | ) |

| (1) | Adjusted to give effect to                                            
 1-for-35 reverse stock split that became effective on April 15, 2025. |

109

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read together with the consolidated financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth in the sections of this prospectus titled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.”

Overview

We are an innovative
revenue-generating company focused on acquiring, developing and commercializing non-opioid management products for the treatment of acute and chronic pain